Matthew S. Schwartz
Matthew S. Schwartz is a reporter with NPR's news desk. Before coming to NPR, Schwartz worked as a reporter for Washington, DC, member station WAMU, where he won the national Edward R. Murrow award for feature reporting in large market radio. Previously, Schwartz worked as a technology reporter covering the intricacies of Internet regulation. In a past life, Schwartz was a Washington telecom lawyer. He got his J.D. from Georgetown University Law Center, and his B.A. from the University of Michigan ("Go Blue!").
-
The virus is the enemy, NIH Director Francis Collins said. "It's not the other people in the other political party." Omicron, which could soon become the dominant strain, is extremely infectious. -
Military officials say that, after months of warnings, they have begun disciplinary actions. The Army has reprimanded 2,700 soldiers and said it will begin discharge proceedings in the new year. -
The respected journalist, who kept the news of his exit secret from colleagues, will head to CNN's new streaming service. -
State AG Dana Nessel said her office is the "perfect agency" to conduct a full review of the shooting that killed four students. The investigation would focus on the events leading up to the tragedy. -
After recovering from wounds suffered in World War II, Dole went on to represent Kansas in Congress for more than 30 years. -
The agreement came days before Iran was likely to be censured for failing to cooperate with the International Atomic Energy Agency. -
Heavy rain could start late Sunday and run through at least Tuesday, causing flooding, high winds and deadly storm surge. -
Investigations from The New York Times and The Washington Post call into question a recent U.S. military drone strike against an alleged ISIS-K sympathizer. -
President Biden said on Sunday that the U.S. has evacuated nearly 28,000 people from Afghanistan since Aug. 14. But he said there is "no way to evacuate this many people without pain and loss." -
Regeneron's antibody cocktail, authorized by the Food and Drug Administration, treats COVID-19 symptoms in people who are at high risk of developing severe symptoms.
